The market outlook from the perspective of many biotech CEOs is grim. When the investment environment stabilized following ...

SAN JOSE -- A Stanford University genetics professor has paid nearly $30 million in restitution after a judge determined that he misled investors in a now-dissolved biotechnology company he founded.

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...

Washington, DC, May 08, 2025 (GLOBE NEWSWIRE) -- A new survey conducted by Incubate reveals rising concern among early-stage biotech executives that federal health policies are chilling investment ...

hosted “Impulse,” among Stanford’s premier biotechnology conferences, bringing together a community of students building products and technology for healthcare and biomedicine. The annual ...

At Stanford’s Drug Discovery Symposium, biotech bigwigs spoke openly this week about how the scientific ecosystem that trains the industry’s workforce and produces many of the discoveries ...

Biotech has long been recognized as one of the most speculative industries to invest in, precisely because most of its early-stage companies rely on securing funding for research and development ...